Skip to content

Prospective Registry of Acute Coronary Syndromes in Ferrara

Acute coRonary sYndrOmes proSpective regisTry Of Ferrara

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02438085
Acronym
ARYOSTO
Enrollment
10000
Registered
2015-05-08
Start date
2014-06-30
Completion date
2032-11-30
Last updated
2023-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndromes

Keywords

acute coronary syndromes, outcome, medical management, comorbidities, registry

Brief summary

The ARYOSTO has been designed to describe the clinical epidemiology and the current management of acute coronary syndromes (ACS) in the area of Ferrara. Especially, the Authors will evaluate the medical and interventional management of ACS patients admitted to hospitals in the area of Ferrara and receiving coronary artery angiography and percutaneous coronary intervention (PCI) in the hub center of Ferrara (Azienda Ospedaliera Universitaria di Ferrara, Cona (FE), Italy)

Detailed description

The Cardiovascular Institute of the University Hospital of Ferrara is the hub center of the area of Ferrara (400.000 residents). The cath-lab of the University Hospital of Ferrara is the hub center of the network for the management of patients with ACS. This finding guarantees a very high number of patients with ACS admitted to University Hospital of Ferrara (more than 1500 by year). In the cath-lab are performed more than 2000 coronary artery angiography by year and more than 1100 PCI by year. The staff of the cardiology unit has a great experience in the management of studies (investigator-driven, randomized controlled trials, with or without sponsor) enrolling patients with ACS and treated with PCI. All consecutive patients with ACS admitted to hospitals of the Ferrara area will be included in the registry. All data will be related to long-term clinical outcome. METHODS: Prospective collection of following data: * baseline characteristics including cardiovascular (CV) risk factors, CV history and comorbidities (see below) * clinical management (CV drugs, imaging exams, diagnostic exams, time to cath-lab access) * biomarkers evaluating inflammation, endothelial, platelet, thrombotic function and activation * procedural details including coronary disease description, intervention modality, stent, coronary imaging, CV drugs during intervention, procedural complications and management, access site * in-hospital adverse events * medical treatment at discharge and during the follow-up * clinical follow-up (1, 2, 3, 4 5 years) PRE-SPECIFIED SUBSTUDY The Authors will focus the attention in specific subset of patients: * patients with diabetes * patients with chronic obstructive pulmonary disease * patients with chronic kidney disease * patients with rheumatologic disordes * patients with malignancy In these subsets of patients the Authors will collect a more detailed description of symptoms, clinical presentation, disease management and relationship between comorbidity and ACS. Similarly, a specifc substudy of the registry will be focused on the characterization of coronary artery disease and of atherosclerotic plaque morphology in patients with comorbidities (diabetes, COPD, CKD, malignancy) as compared to patients without comorbidities. Finally, the Authors will evaluate the quality of life of ACS patients in the area of Ferrara applying at 1, 2, 3, 4 and 5 years the following questionnaires: EQ-5D and SF-12 v2

Interventions

OTHERprospective collection of data and follow-up

prospective collection of data and follow-up of all patients admitted to hospital for ACS

Sponsors

University Hospital of Ferrara
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age \>18 years * hospital admission for acute coronary syndromes * resident in the Ferrara area

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
1-year combined primary endpoint1 year1-year occurence of cardiac death, myocardial infarction, cerebrovascular accident

Secondary

MeasureTime frameDescription
2-year combined endpoint2 years2-year occurence of cardiac death, myocardial infarction, cerebrovascular accident
3-year combined endpoint3 years3-year occurence of cardiac death, myocardial infarction, cerebrovascular accident
5-year combined endpoint5 years5-year occurence of cardiac death, myocardial infarction, cerebrovascular accident
primary safety outcome1 year1 year occurrence of BARC 2-3 bleedings
cardiac adverse events1, 2, 3, 4, 5 yearshospital admission heart failure, arrhytmias, acute coronary syndromes, admission to emergency room for chest pain
respiratory adverse events1, 2, 3, 4, 5 yearshospital admission for respiratory cause
annual occurrence of single components of primary endpoint1, 2, 3, 4, 5 yearsoccurrence of each component of the primary endpoint

Other

MeasureTime frameDescription
emergency room admittance1, 2, 3, 4, 5 yearsassessment of number of admission to emergency room for any causes

Countries

Italy

Contacts

Primary ContactVeronica Lodolini, BSc
veronica.lodolini@student.unife.it+390532236450

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026